De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Monopar Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Monopar Therapeutics' is Chandler Robinson, benoemd in Dec2014, heeft een ambtstermijn van 9.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.78M, bestaande uit 32.6% salaris en 67.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.51% van de aandelen van het bedrijf, ter waarde $ 358.47K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.6 jaar en 8.7 jaar.
Belangrijke informatie
Chandler Robinson
Algemeen directeur
US$1.8m
Totale compensatie
| Percentage CEO-salaris | 32.6% |
| Dienstverband CEO | 9.8yrs |
| Eigendom CEO | 1.5% |
| Management gemiddelde ambtstermijn | 5.6yrs |
| Gemiddelde ambtstermijn bestuur | 8.7yrs |
Recente managementupdates
Recent updates
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Aug 13
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?
Feb 27Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?
Mar 02We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Nov 16Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive
Oct 05We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate
Jul 30Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans
Mar 28We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely
Jul 15Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation
Mar 26Monopar nabs U.S. patent covering camsirubicin
Dec 22Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19
Dec 10Monopar launches validive mid-stage study in chemo-induced oral mucositis
Dec 08Monopar Therapeutics EPS beats by $0.02
Nov 12Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$2m | US$580k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$2m | US$550k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$10m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | US$1m | US$525k | -US$9m |
| Sep 30 2021 | n/a | n/a | -US$9m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$7m |
| Dec 31 2020 | US$2m | US$504k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$5m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | n/a | n/a | -US$4m |
| Dec 31 2019 | US$541k | US$386k | -US$4m |
| Sep 30 2019 | n/a | n/a | -US$4m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$4m |
| Dec 31 2018 | US$1m | US$375k | -US$3m |
| Sep 30 2018 | n/a | n/a | -US$3m |
| Jun 30 2018 | n/a | n/a | -US$17m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | US$401k | US$331k | -US$17m |
Compensatie versus markt: De totale vergoeding ($USD 1.78M ) Chandler } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).
Compensatie versus inkomsten: De vergoeding van Chandler is gestegen terwijl het bedrijf verliesgevend is.
CEO
Chandler Robinson (40 yo)
9.8yrs
Tenure
US$1,778,655
Compensatie
Dr. Chandler D. Robinson, M.D., MBA, MSc, Co-Founded Monopar Therapeutics Inc. in 2010 and has been Chief Executive Officer and Director since December 2014 and serves as President. Among his previous expe...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Independent Executive Chairman of the Board | 9.8yrs | US$264.04k | 0.43% $ 68.5k | |
| Co-Founder | 9.8yrs | US$1.78m | 1.51% $ 242.0k | |
| Chief Operating Officer | 3.3yrs | US$911.14k | 1.1% $ 175.7k | |
| CFO, Principal Accounting Officer & Principal Financial Officer | less than a year | geen gegevens | geen gegevens | |
| Acting Chief Medical Officer | 7.8yrs | geen gegevens | geen gegevens |
5.6yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van MNPR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Independent Executive Chairman of the Board | 9.8yrs | US$264.04k | 0.43% $ 68.5k | |
| Co-Founder | 9.8yrs | US$1.78m | 1.51% $ 242.0k | |
| Independent Director | 9.8yrs | US$126.04k | 1.34% $ 214.6k | |
| Independent Director | 7.5yrs | US$136.54k | 0.15% $ 24.4k | |
| Independent Director | 7.2yrs | US$128.54k | 0.18% $ 28.1k | |
| Director | 1.6yrs | US$848.44k | 0.33% $ 52.3k |
8.7yrs
Gemiddelde duur
65.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van MNPR wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.7 jaar).